+
+
Stay Informed
STRUCTURAL INTERVENTIONS

AMPLATZER™ TALISMAN™
PFO OCCLUDER

Effective PFO closure is made easier with the Amplatzer™ Talisman™ PFO Occluder.1 For patients who have experienced a PFO-associated stroke, clinical data show they can benefit from PFO closure, with this minimally invasive procedure significantly reducing the risk of recurrent ischemic stroke and offering an excellent safety profile.2-4 

THE PIONEER 
IN PFO CLOSURE1

The Amplatzer™ Talisman™ PFO Occluder set the standard as the first device supported by positive PFO trial results, developed specifically for patent foramen ovale (PFO) closure to reduce the risk of recurrent ischemic stroke.2 Our clinical evidence is unmatched, thanks to the largest-ever trial for PFO closure, boasting 5,810 patient-years of data.2

Today, with over 250,000 patients treated worldwide and a legacy spanning over 25 years, it is the #1 device worldwide.1

New data on Patients >60 years old

The device you know, just got better.

Built on the proven Amplatzer PFO closure technology with key enhancements:

  • New 30mm device for the complete PFO portfolio for every case
  • Device now pre-loaded onto the Amplatzer Talisman delivery cable, simplifying preparation and enhancing ease-of-use

The PFO Occluder trusted by thousands of physicians around the world1

250K+

Global implants1


We set the standard

  • Pioneered treatment with a PFO-specific device
  • Available in over 80 countries around the world

5,810

PATIENT-YEARS OF DATA2


We raise the bar

  • With the landmark RESPECT trial, we had the most extensive patient follow-up, almost 2x more than other PFO trials
  • RESPECT was also the only trial to include patients on anticoagulation therapy, a real-world cross-section of patients

990

PATIENTS IMPLANTED WITH DEVICE IN RCTS2,4-8


We demonstrate excellence

  • ZERO device erosions, thrombus, embolization events or wire frame fractures in 6 published trials with 990 patients
  • 94.2% effective closure rate at 6 months

PFO closure reduces the risk of another stroke in patients 18-60 by 59% vs. medical management alone.9

For patients who have experienced a PFO-associated stroke, the thought of a recurrence can generate anxiety. Determining and delivering the most effective treatment soon after a stroke is critically important to provide these patients peace of mind.

For more patient and caregiver resources and to learn more, head to www.PFOStroke.com

In a real-world analysis of patients >60 years with presumed PFO-associated stroke, patients
who received the Amplatzer Talisman PFO Occluder saw a 38% relative risk reduction of recurrent ischemic stroke over non-closure patients.10

Watch the webinar on new PFO >60 years data

Alan's story

At age 37, Alan went from being a healthy, active individual to having a stroke. Learn how the Amplatzer PFO Occluder eased his fears of suddenly having another stroke to living an energetic, hopeful life.

This testimonial relates an account of an individual’s response to the treatment. This patient’s account is genuine, typical and documented. However, it does not provide any indication, guide, warranty or guarantee as to the response other persons may have to the treatment. Responses to the treatment discussed can and do vary and are specific to the individual patient.

KEY FEATURES

Often Imitated,
Never Matched1,11

Unique design features set the Amplatzer Talisman PFO Occluder apart from the rest.

*Only the 18 mm size is not asymmetric.
†Effective closure.

Amplatzer PFO Occluder demonstrated over 94 percent closure rate in clinical trial

*Only the 18 mm size is not asymmetric.

Minimizing Complexity in PFO Closure

SIMPLIFIED
PREP

Occluder comes assembled to the flexible Trevisio™ delivery cable, ready to use

Amplatzer PFO Occluder comes assembled to Trevisio delivery cable, ready to use

RECAPTURABLE AND REPOSITIONABLE

Self-expanding discs align to the PFO without an additional “locking” step and can be adjusted for ideal placement
 

Amplatzer PFO Occluder is recapturable and repositionable for better PFO closure

LOW-PROFILE
DELIVERY

8 F and 9 F introducer sheaths enable treatment of patients with smaller vasculature

Amplatzer PFO Occluder offers options for patients with smaller vasculature

Physician education

Hear the latest on real world outcomes with the Amplatzer Talisman PFO Occluder in patients >60 years

VIEW All Webinars

Abbott Amplatzer Portfolio App helps physicians determine which structural intervention device to use


GET THE AMPLATZER PORTFOLIO APP

The Amplatzer Portfolio App helps physicians determine which Amplatzer Structural Interventions device to use by suggesting applicable devices based on respective Instructions for Use.
 

App Store
Google Play

MAT-2010605 v7.0 | Item approved for OUS use only.

References
  1. Data on file at Abbott.
  2. Saver JL, Carroll JD, Thaler DE, Smalling RW, MacDonald LA, Marks DS, Tirschwell DL. 2017. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med, 377(11), 1022-1032
  3. Sondergaard L, Kasner SE, Rhodes JF, Andersen G, Iversen HK, Nielsen-Kudsk JE, Settergren M, Sjostrand C, Roine RO, Hildick-Smith D, Spence JD, Thomassen L. 2017. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med, 377(11), 1033-1042
  4. Mas JL, Derumeaux G, Guillon B, Massardier E, Hosseini H, Mechtouff L, Arquizan C, Bejot Y, Vuillier F, Detante O, Guidoux C, Canaple S, Vaduva C, Dequatre-Ponchelle N, Sibon I, Garnier P, Ferrier A, Timsit S, Robinet-Borgomano E, Sablot D, Lacour JC, Zuber M, Favrole P, Pinel JF, Apoil M, Reiner P, Lefebvre C, Guerin P, Piot C, Rossi R, Dubois-Rande JL, Eicher JC, Meneveau N, Lusson JR, Bertrand B, Schleich JM, Godart F, Thambo JB, Leborgne L, Michel P, Peirard L, Turc G, Barthelet M, Charles-Nelson A, Weimar C, Moulin T, Juliard JM, Chatellier G. 2017. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med, 377(11), 1011-1021
  5. Tobis JM, Charles A, Silberstein SD, Sorensen S, Maini B, Horwitz PA, Gurley JC. 2017. Percutaneous closure of patent foramen ovale in patients with migraine: The PREMIUM trial. J Am Coll Cardiol, 70(22), 2766-2774
  6. Meier B, Kalesan B, Mattle HP, Khattab AA, Hildick-Smith D, Dudek D, Andersen G, Ibrahim R, Schuler G, Walton AS, Wahl A, Windecker S, Juni S. 2013. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med, 368(12), 1083-1091
  7. Lee PH, Song JK, Kim JS, Heo R, Lee S, Kim DH, Song JM, Kang DH, Kwon SU, Kang DW, Lee D, Kwon HS, Yun SC, Sun BJ, Park JH, Lee JH, Jeong HS, Song HJ, Kim J, Park SJ. 2018. Cryptogenic stroke and high-risk patent foramen ovale: The DEFENSE-PFO trial. J Am Coll Cardiol, 71(20), 2335-2342
  8. Mattle HP, Evers S, Hildick-Smith D, Becker WJ, Baumgartner H, Chataway J, Gawel M, Gobel H, Heinze A, Horlick E, Malik I, Ray S, Zermansky A, Findling O, Windecker S, Meier B. 2016. Percutaneous closure of patent foramen ovale in migraine with aura, a randomized controlled trial. Eur Heart J, 37(26), 2029-2036
  9. Kent DM, Saver JL, Kasner SE. 2021. Heterogeneity of treatment effects in an analysis of pooled individual patient data from randomized trials of device closure of patent foramen ovale after stroke. JAMA 326(22), 2277-2286
  10. Saver JL et al. 2024. Device closure of patent foramen ovale in patients >60 years with ischemic stroke: Results from US Medicare beneficiaries ESOC
  11. Stähli BE, Nietlispach F, Meier, B. (2020). Chapter 14 - Percutaneous PFO Closure: History, Devices, Techniques, Safety, and Informed Consent. In M Khalid Mojadidi, B Meier, JM Tobis (Ed.). Patent Foramen Ovale Closure for Stroke, Myocardial Infarction, Peripheral Embolism, Migraine, and Hypoxemia (pp. 171-184). Academic Press
  12. Chemical Characterization Testing Data on File.
Abbott Logo

Follow Abbott

Copyright © 2025 Abbott, 3200 Lakeside Dr, Santa Clara, 95054, U.S.A.
Caution: Product(s) are intended for use by or under the direction of a physician. Prior to use, reference to the Instructions for Use, inside the product carton (when available) or at www.eifu.abbott for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.
Illustrations are artist’s representations only and should not be considered as engineering drawings or photographs. Photos on file at Abbott.
Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates.
No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

MAT-2000631 v20.0 | Item approved for OUS use only.

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of the product that are not approved in other countries or regions.

U.S. Health Care Professionals International Health Care Professionals

YOU ARE ABOUT TO LEAVE
www.structural­heart.abbott

You are now leaving www.structuralheart.abbott. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.

OkCancel
+